Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00465023 |
Recruitment Status
:
Completed
First Posted
: April 24, 2007
Last Update Posted
: January 20, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatocellular Cancer Cholangiocarcinoma Hepatic Metastases | Procedure: Proton Beam Radiation | Not Applicable |
- Participants will receive treatment as an outpatient at the Northeast Proton Treatment Center located at the Massachusetts General Hospital.
- Since we are looking for the highest dose of proton beam radiation that can be given to people safely, not everyone who participates in this study will be receiving the same amount of radiation. Small groups of people will be enrolled and given a certain dose of radiation. If they tolerate it well, the next small group of people enrolled will receive a higher dose. This will continue until we find the highest dose that can be given without causing serious or unmanageable side effects.
- Radiation treatment to the liver will be given once a day, 5 days a week (Monday-Friday), for 3 weeks. Each treatment takes about 10-20 minutes.
- A physical examination, medical history, and blood tests will be taken once a week for 3 weeks during radiation therapy. Follow-up visits will occur every 3 months for 2 years, and every 6 months thereafter for 3 years, and then annually thereafter.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 16 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases |
Study Start Date : | June 2003 |
Actual Primary Completion Date : | September 2013 |
Actual Study Completion Date : | January 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Proton Beam Radiation
Proton radiation therapy
|
Procedure: Proton Beam Radiation
Once a day, 5 days a week (Monday-Friday) for 3 weeks.
|
- To determine the maximum tolerated dose (MTD) of proton beam irradiation in patients with unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases. [ Time Frame: 4 years ]
- To determine safety and tolerance of this treatment program [ Time Frame: 4 years ]
- to evaluate tumor response, local control and survival in this patient population.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Biopsy proven unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.
- Primary lesion size of 6cm or less in greatest diameter
- Single or multinodular tumors (up to 3)
- 18 years of age or older
- No evidence of extrahepatic tumor
- Karnofsky performance status of 70-100
- If patient has underlying cirrhosis, only Child's classification Group A or Group B
- Adequate renal function
- Expected survival of greater than three months
Exclusion Criteria:
- Pregnant or lactating women
- Evidence of non-hepatic metastatic disease
- Local conditions or systemic illnesses which would reduce the local tolerance to radiation treatment, such as serious local injuries, active collagen vascular disease, etc.
- Prior radiation treatment to affected region
- Serious psychiatric illness which would limit compliance with treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00465023
Principal Investigator: | Theodore S. Hong, MD | Massachusetts General Hospital |
Responsible Party: | Theodore Sunki Hong, Attending Radiation Oncologist, Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00465023 History of Changes |
Other Study ID Numbers: |
03-084 |
First Posted: | April 24, 2007 Key Record Dates |
Last Update Posted: | January 20, 2017 |
Last Verified: | January 2017 |
Keywords provided by Theodore Sunki Hong, Massachusetts General Hospital:
proton beam irradiation liver cancer |
Additional relevant MeSH terms:
Neoplasm Metastasis Cholangiocarcinoma Liver Neoplasms Neoplastic Processes Neoplasms Pathologic Processes Adenocarcinoma |
Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases |